Study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder - Trial 2015-004905-17

Name: Clinical Trial 2015-004905-17
Creator: GlaxoSmithKline Research & Development
Keywords: Major Depressive Disorder, clinical trial

Access comprehensive clinical trial information for 2015-004905-17 through Pure Global AI's free database. This phase not specified trial is sponsored by GlaxoSmithKline Research & Development and is currently status unknown. The study focuses on Major Depressive Disorder.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2015-004905-17

Trial Details

EU Clinical Trials Register • 2015-004905-17

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder

Study Focus

Disease/Condition

Major Depressive Disorder

Sponsor & Location

Primary Sponsor

GlaxoSmithKline Research & Development

Funder

GlaxoSmithKline

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

Change from baseline in the CDRS-R total score at Week 8 [Time Frame: Baseline and Week 8]

ICD-10 Classifications

Recurrent depressive disorder

Recurrent depressive disorder, unspecified

Depressive conduct disorder

Other recurrent depressive disorders

Recurrent depressive disorder, current episode moderate

Data Source

Registry

EU Clinical Trials Register

Trial ID

2015-004905-17

Type

Non-Device Trial